Our goal is to make biological drugs accessible

Biological drugs have revolutionized the treatment of many serious diseases such as cancer, rheumatoid arthritis, psoriasis and macular degeneration. The only problem is that they are so expensive that only a fraction of those affected can be treated with them. Our goal is to make biological drugs accessible to everyone who needs them.

About Us
We strive towards the lowest possible production cost

We base the development of our Biosimilars on the patented platform technology that can provide up to 12 times productivity and thereby up to an 80% cost reduction compared to standard systems in the development of biological drugs.

Our Technology
We are building a world-leading biosimilar developer

We develop biosimilars in treatment of macular degeneration ( Xlucane™), rheumatoid arthritis and psoriasis (BIIB801) and cancer (Xdivane™) addressing originator sales of over SEK 100 billion

Our Products

0

Employees

0

Patents and patent applications

0

Biosimilars under development

Fraudulent attempts to use Xbrane's name

We want to inform our customers, partners, and other stakeholders that we have become aware of fraudulent attempts to use Xbrane’s name, particularly fake recruitment services. We take the security of our customers and business relationships very seriously and, therefore, emphasize the importance of remaining vigilant.

Please note that Xbrane does not engage in external advertisements for recruitment purposes. Our official recruitment communication channels are limited to our website (https://www.xbrane.com), email addresses ending with @xbrane.com, and our company page on LinkedIn (https://www.linkedin.com/company/xbrane-bioscience-ab).

Interview with CEO Martin Åmark, October 2023

At Xbrane Biopharma

Press Releases

20 Mar 2025

Notice of Extra General Meeting in Xbrane Biopharma AB

20 Mar 2025

Xbrane has entered into an agreement to sell XB003 (Cimzia biosimilar candidate) and parts of its organization to Alvotech for a total consideration of SEK 275 million

20 Feb 2025

Xbrane Biopharma releases Year-end Report 2024

17 Feb 2025

Invitation to presentation of Xbrane Biopharma’s Year-end report 2024 on February 20, 2025

31 Jan 2025

The number of shares and votes in Xbrane has changed as a result of 2,706,898 shares being issued during January through the exercise of warrants in December 2024.

09 Jan 2025

Xbrane Biopharma AB (publ) (“Xbrane” or “the company) appoints Jane Benyamin as acting Chief Financial Officer.

31 Dec 2024

XBRANE RE-SUBMITS BLA FOR RANIBIZUMAB BIOSIMILAR CANDIDATE TO FDA

18 Dec 2024

Xbrane announces outcome of exercise of warrants of series TO1

02 Dec 2024

XBRANE BIOPHARMA’S PRINCIPAL OWNER SYSTEMATIC GROUP PROVIDES A SHORT-TERM LOAN OF SEK 20 M TO THE COMPANY